Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 5, pp 1726–1732 | Cite as

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Children, Adolescents, and Young Adults: The First 50 Cases

  • Andrea Hayes-Jordan
  • Holly Green
  • Heather Lin
  • Pascal Owusu-Agyemang
  • Rodrigo Mejia
  • Regina Okhuysen-Cawley
  • Jose Cortes
  • Nancy E. Fitzgerald
  • Mary Frances McAleer
  • Cynthia Herzog
  • Winston W. Huh
  • Peter Anderson
Pediatric Oncology

Abstract

Background

Extensive peritoneal metastatic disease is rare in children. Although usually manifested as carcinomatosis in adults, sarcomatosis is more common in children. The authors began a pediatric hyperthermic intraperitoneal chemotherapy (HIPEC) program, and this report describes their initial results from the first 50 pediatric, adolescent, and young adult patients.

Methods

A single-institution, retrospective study investigated the first 50 cytoreductive surgeries and HIPEC by one surgeon for patients 3–21 years of age. The HIPEC was added to chemotherapy and radiotherapy treatment. Demographics, outcome, and complications were recorded.

Results

The median follow-up period for the surviving patients was 21.9 months. The most common diagnoses were desmoplastic small round cell tumor (n = 21), rhabdomyosarcoma (n = 7), mesothelioma (n = 4), and other carcinoma (n = 17). Multivariate analysis showed that patients treated with HIPEC and an incomplete cytoreduction had a greater risk for recurrence than those who had a complete cytoreduction (p = 0.0002). The patients with a higher peritoneal cancer index (PCI) (i.e., a large tumor burden) had a median overall survival (OS) time of 19.9 months relative to the patients with a lower PCI score, who had a median OS of 34 months (p = 0.049). The patients without complete cytoreduction had a median OS of 7.1 months compared with 31.4 months for the patients with complete cytoreduction (p = 0.012). No perioperative mortalities occurred. The incidence of major complications was 28 %.

Conclusion

Cytoreductive surgery and HIPEC with a programmatic approach for patients 3–21 years of age is unique. The best outcome was experienced by patients with desmoplastic small round cell tumor and those with complete cytoreduction. Complete cytoreduction for patients without disease outside the abdominal cavity at the time of surgery affords the best outcome.

Keywords

Overall Survival Soft Tissue Sarcoma Median Overall Survival Rhabdomyosarcoma Cytoreductive Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

This study was supported in part by MD Anderson’s Cancer Center Support Grant CA016672.

Conflict of interest

There are no conflicts of interest.

References

  1. 1.
    Hayes-Jordan A, Anderson P, Curley S, et al. Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor. J Pediatr Surg. 2007;42:E29–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Iwasaki M, Kitaguchi K, Kobayashi H. Mesenteric leiomyosarcoma in a 13-year-old boy. J Pediatr Surg. 2010;45:1893–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Kaste SC, Marina N, Fryrear R, et al. Peritoneal metastases in children with cancer. Cancer. 1998;83:385–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Pawel BR, de Chadarevian JP, Inniss S, Kalwinski P, Paul SR, Weintraub WH. Mesenteric pleomorphic liposarcoma in an adolescent. Arch Pathol Lab Med. 1997;121:173–6.PubMedGoogle Scholar
  5. 5.
    Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC. Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer. 2004;101:39–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Prakash S, Sarran L, Socci N, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol. 2005;27:179–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Gerald WL, Ladanyi M, de Alava E, et al. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol. 1998;16:3028–36.PubMedGoogle Scholar
  8. 8.
    Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol. 1999;6:582–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994;54:2837–40.PubMedGoogle Scholar
  10. 10.
    Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP. Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg. 2005;40:251–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  12. 12.
    Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. Wiley, Hoboken, NJ, 2002.CrossRefGoogle Scholar
  13. 13.
    Hayes-Jordan A, Green H, Ludwig J, Anderson P. Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. Pediatr Blood Cancer. 2012;59:395–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Green H, Lin H, Owusu-Agyemang P, et al. Perioperative renal protective reatment avoids renal toxicity in pediatric and adult patients undergoing HIPEC with cisplatin. J Pediatr Oncol. 2014.Google Scholar
  15. 15.
    Roviello F, Caruso S, Marrelli D, et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol. 2010;20:e38–54.CrossRefPubMedGoogle Scholar
  16. 16.
    Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Gil A, Gomez Portilla A, Brun EA, Sugarbaker PH. Clinical perspective on desmoplastic small round-cell tumor. Oncology. 2004;67:231–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Baumgartner JM, Ahrendt SA, Pingpank JF, et al. Aggressive locoregional management of recurrent peritoneal sarcomatosis. J Surg Oncol. 2013;107:329–34.CrossRefPubMedGoogle Scholar
  21. 21.
    Karakousis CP, Blumenson LE, Canavese G, Rao U. Surgery for disseminated abdominal sarcoma. Am J Surg. 1992;163:560–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Lim SJ, Cormier JN, Feig BW, et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol. 2007;14:2309–18.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Andrea Hayes-Jordan
    • 1
    • 5
  • Holly Green
    • 2
  • Heather Lin
    • 3
  • Pascal Owusu-Agyemang
    • 4
  • Rodrigo Mejia
    • 2
  • Regina Okhuysen-Cawley
    • 7
  • Jose Cortes
    • 2
  • Nancy E. Fitzgerald
    • 6
  • Mary Frances McAleer
    • 7
  • Cynthia Herzog
    • 2
  • Winston W. Huh
    • 2
  • Peter Anderson
    • 8
  1. 1.Department of Surgical OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of PediatricsUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of BiostatisticsUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Department of Anesthesiology & Perioperative MedicineUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  5. 5.Department of Diagnostic RadiologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  6. 6.Department of Radiation OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  7. 7.Department of Pediatric MedicineTexas Children’s HospitalHoustonUSA
  8. 8.Department of Pediatrics/Hematology-/Oncology & BMT and Cell Therapy, Levine Children’s Hospital/Levine Cancer InstituteCarolinas Healthcare SystemCharlotteUSA

Personalised recommendations